Ambagon Therapeutics

Biotech · San Carlos, US

US-Dutch biotech developing molecular-glue cancer therapeutics.

Founders

Christian Ottmann (Germany · ♂) — A leading academic in 14-3-3 protein biology, he co-founded Ambagon as CTO to turn his molecular-glue research into drugs that stabilize protein interactions on hard-to-drug cancer targets.
Michelle Arkin (United States · ♀) — A UCSF expert in drugging protein-protein interactions, she co-founded Ambagon to advance molecular glues targeting disordered proteins.
Luc Brunsveld (Netherlands · ♂) — A chemical-biology professor at TU Eindhoven, he co-founded Ambagon to commercialize 14-3-3 molecular-glue science for difficult oncology targets.

Date	Round	Amount
Jan 2022	Series A US-Dutch biotech Ambagon Therapeutics raised an 85M dollar Series A led by Nextech Invest, with RA Capital, Inkef Capital and AbbVie Ventures.	$75.1M

Tap an investor to see what else they have backed.

Data is community-curated and may be incomplete.